| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP,General Counsel, Secretary | EVP & General Counsel
1 company
Austin D. Kim last filed a Form 4 in January 2024, as EVP,General Counsel, Secretary at ACAD. Austin D. Kim's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Austin D. Kim a middling insider score of 66/100, based on 11 past trades. Over a 12-month horizon, 72.7% of those trades were profitable, with an average 12-month return of +8.0%.
At the last filing, the largest reported position was 46,901 shares of ACAD. The ACAD filings lean toward selling, a net 54,135 shares.
Austin D. Kim has 21 Form 4 filings on record from July 2018 to January 2024, all as EVP,General Counsel, Secretary at Acadia Pharmaceuticals (ACAD), 2018–2024.
The 42 reported transactions were 15 open-market sales, 14 option exercises, 12 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 15 sales worth about $1.9M.
The largest open-market sale was 17,500 shares of ACAD at an average $45.06 on December 11, 2019, about $789K.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from January 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 590 | $29.96 | $17,676.40 | -1.2% | -40.9% | -42.3% | |
| Oct 6, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 16,369 | $21.96 | $359,463.24 | -26.3% | +38.1% | -30.4% | |
| May 1, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 917 | $21.18 | $19,422.06 | -3.5% | +34.4% | -23.2% | |
| Apr 6, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 1,456 | $18.16 | $26,440.96 | -5.9% | +31.7% | -1.9% | |
| Feb 24, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 803 | $18.78 | $15,080.34 | -3.8% | +29.2% | +31.0% | |
| Jan 9, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 589 | $17.13 | $10,089.75 | -3.1% | +5.6% | +81.9% | |
| May 2, 2022 | ACAD Acadia Pharmaceuticals Inc | EVP,General Counsel, Secretary | Sale+OE | 894 | $18.18 | $16,254.71 | -5.1% | -27.8% | +9.4% | |
| Feb 23, 2022 | ACAD Acadia Pharmaceuticals Inc | EVP & General Counsel | Sale+OE | 782 | $23.80 | $18,611.60 | -5.1% | -35.3% | -22.6% | |
| Jan 6, 2022 | ACAD Acadia Pharmaceuticals Inc | EVP & General Counsel | Sale+OE | 574 | $23.05 | $13,230.70 | -4.2% | +16.4% | -26.0% | |
| Apr 30, 2021 | ACAD Acadia Pharmaceuticals Inc | EVP & General Counsel | Sale+OE | 1,054 | $20.33 | $21,427.82 | -8.5% | +8.4% | -10.3% |